WEB NEWS Comments & Business Outlook
For the Year Ended
For the period
from inception
(August 13, 2010)
to
December 31, 2011
December 31, 2010
Revenues
$
99,192
$
164,095
Cost of goods sold
51,059
86,109
Gross margin
48,133
77,986
Operating Expenses
Research and development
222,058
229,753
Sales and marketing
507,168
32,308
General and administrative
1,510,374
270,913
Employee Stock Based Compensation
3,132,408
-
Non-Employee Stock Based Compensation
12,708,115
-
18,080,123
532,974
Loss from operations
(18,031,990
)
(454,988
)
Other income (expense)
Interest expense
(304,038
)
-
Change in fair value of derivative liabilities
(14,502,727
)
-
(14,806,765
)
-
Loss before income taxes
(32,838,755
)
(454,988
)
Provision for income taxes
-
-
Net loss
$
(32,838,755
)
$
(454,988
)
Loss per share:
Basic & Diluted
$
(1.77
)
$
(0.01
)
Weighted-average shares outstanding:
Basic & Diluted
18,534,764
33,577,921
Deal Flow
Between February 24, 2012 and February 29, 2012, Intellicell Biosciences, Inc. (the “Company”)
entered into securities purchase agreements with accredited investors, as defined in Regulation D promulgated under the Securities Act of 1933, as amended (the “Securities Act”), pursuant to which the Company sold (i) an aggregate of
435,000 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), (ii) class A warrants to purchase an aggregate of 870,000 shares of Common Stock (the “Class A Warrants”), and (iii) class B warrants to purchase an aggregate of
870,000 shares of Common Stock (the “Class B Warrants” and together with the Class A Warrants, the “Warrants”), for aggregate gross cash proceeds of $435,000. To date, the Company has sold its Common Stock and Warrants for aggregate gross proceeds of
$2,475,000 , which consisted of
$1,975,000 of cash and the exchange and cancelation of a promissory note (bearing principal and interest totaling
$500,000) and a warrant.
Deal Flow
In February 2012, Intellicell Biosciences, Inc. (the “Company”) entered into securities purchase agreements with accredited investors, as defined in Regulation D promulgated under the Securities Act of 1933, as amended (the “Securities Act”), pursuant to which the Company sold (i) an aggregate of 2,040,000 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), (ii) class A warrants to purchase an aggregate of 4,080,000 shares of Common Stock (the “Class A Warrants”), and (iii) class B warrants to purchase an aggregate of 4,080,000 shares of Common Stock (the “Class B Warrants” and together with the Class A Warrants, the “Warrants”), for aggregate gross proceeds of $2,040,000, which consisted of $1,540,000 of cash and the exchange and cancelation of a promissory note (bearing principal and interest totaling $500,000) and a warrant.
Deal Flow
On January 27, 2012, Intellicell Biosciences, Inc. (the “Company”) entered into a
securities purchase agreement with an accredited investor, as defined in Regulation D promulgated under the Securities Act of 1933, as amended (the “Securities Act”), pursuant to which the Company
sold an aggregate of twelve thousand five hundred (
12,500) shares of our series D convertible preferred stock and a warrant to
purchase one hundred twenty-five thousand shares
(125,000) of the Company’s common stock, for aggregate gross proceeds of
$250,000. On December 15, 2011, this same investor had purchased the same number of shares (
12,500) of our series D preferred stock and warrants to purchase the same number of shares of common stock (
125,000) on the same terms and conditions as set forth above, for aggregate gross proceeds of
$250,000.
